Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402956 | 1.00 | KDM4E (0.55) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL5963209 | 0.89 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL5963215 | 0.89 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL7068737 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL7068744 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL19407592 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL25764810 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL25775030 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL1582579 | 0.88 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA2A | |
| SCHEMBL3315671 | 0.88 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | KDM4E 1810/4885TAS1R3 3530/4885TAS1R1 3414/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | KDM4E 1689/4885TAS1R3 3709/4885TAS1R1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.